Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
InCarda Announces RESTORE-1 Phase 3 Trial Results and Continued Development Plans
Details : FlecIH-103 is a novel inhaled drug designed to rapidly deliver flecainide acetate, to the heart via the lungs to restore normal sinus rhythm in patient’s symptoms recurrent PAF.
Product Name : InRhythm
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 30, 2024
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : PhysIQ
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Partnering with physIQ and Syneos Health has allowed to develop and execute a patient-centric strategy to support the Phase 3 program of orally inhaled flecainide (Inrhythm) for acute cardioversion of recent-onset AF.
Product Name : InRhythm
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 24, 2022
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : PhysIQ
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
InCarda Therapeutics Provides Corporate Update Highlighting New Phase 2 Data for InRhythm Program
Details : Based on these positive Phase 2 study results, along with recent interactions with the U.S. Food and Drug Administration (FDA), InCarda plans to conduct a single pivotal Phase 3 trial of InRhythm in patients with recent-onset PAF.
Product Name : InRhythm
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 06, 2021
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Deerfield Management
Deal Size : $30.0 million
Deal Type : Series C Financing
InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing
Details : Proceeds from the financing will be used primarily to fund the ongoing clinical development of InRhythm™ (flecainide for inhalation), the company’s lead program, for the treatment of a recent-onset episode of paroxysmal atrial fibrillation (PAF).
Product Name : InRhythm
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 21, 2020
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Deerfield Management
Deal Size : $30.0 million
Deal Type : Series C Financing
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Innoviva
Deal Size : Undisclosed
Deal Type : Series C Financing
InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing
Details : The European Commission said on Wednesday it had signed a contract on behalf of EU states with U.S. drugmaker Johnson & Johnson for the supply of 400 million doses of its COVID-19 vaccine candidate.
Product Name : InRhythm
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 21, 2020
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Innoviva
Deal Size : Undisclosed
Deal Type : Series C Financing